Howard Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Howard Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.92M	Buy	3,077 +1,737	+130%	+$1.18M	0.02%	199
2026 Q1	$1.04M	Sell	1,340 -1,768	-57%	-$1.35M	0.02%	172
2025 Q4	$2.4M	Buy	3,108 +68	+2%	+$46.2K	0.03%	148
2025 Q3	$1.71M	Sell	3,040 -27	-0.9%	-$15.3K	0.02%	175
2025 Q2	$1.61M	Buy	3,067 +358	+13%	+$200K	0.02%	172
2025 Q1	$1.72M	Sell	2,709 -393	-13%	-$270K	0.04%	143
2024 Q4	$2.21M	Buy	3,102 +89	+3%	+$74.7K	0.03%	140
2024 Q3	$3.17M	Buy	+3,013	New	+$3.35M	0.05%	108
2020 Q4	–	Sell	-366	Closed	-$205K	–	61
2020 Q3	$205K	Buy	366 +27	+8%	+$16.4K	0.05%	51
2020 Q2	$214K	Buy	+339	New	+$192K	0.06%	49

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Howard Capital Management's REGN Position: Q2 2026 in Review

Howard Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 130% in Q2 2026, buying an estimated $1.18M and bringing the position to 3,077 shares worth $1.92M. The position accounts for 0.02% of the portfolio, ranked #199.

Howard Capital Management first reported a position in REGN in Q2 2020 and has held it in 10 quarters since. The position peaked at $3.17M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Howard Capital Management held 3,077 shares of Regeneron Pharmaceuticals worth $1.92M as of Q2 2026.
Howard Capital Management bought 1,737 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.18M.
Regeneron Pharmaceuticals made up 0.02% of Howard Capital Management's portfolio in Q2 2026, its #199 holding.
Howard Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 10 quarters since.
Howard Capital Management's Regeneron Pharmaceuticals position peaked at $3.17M in Q3 2024.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Howard Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.